Gregg Smith

Gregg Smith is an accomplished senior executive with over 20 years of international experience in the biotech and pharmaceutical industry. They played a key role in the development of the myelofibrosis therapy momelotinib, which was sold to GSK for $1.9 billion. Gregg's extensive drug development expertise includes leadership in both preclinical and clinical programs, along with significant involvement in FDA regulatory interactions. Currently, they serve as a Director at Gregg Smith Consulting and hold senior advisory roles at several companies, while also pursuing an MBA in Technology Management from La Trobe University.